Bristol Myers Squibb Acquires Neuroscience-Focused Karuna Therapeutics 

Bristol Myers Squibb (BMS) is set to acquire Karuna Therapeutics, a biopharmaceutical company which is focused on treatments for psychiatric and neurological conditions. BMS said the deal has a total equity value of $14 billion. The transaction has been approved by the boards of both companies and is expected to close in the first half of 2024, pending regulatory approvals.  

Karuna’s KarXT (xanomeline-trospium), its lead asset, is an antipsychotic that targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile. It has demonstrated improvements in cognition and is not associated with common . . .